Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma

1 Aug 2016

Abstract excerpt

Diffuse large B cell lymphomas (DLBCLs) arise from proliferating B cells transiting different stages of the germinal center reaction. In activated B cell DLBCLs (ABC-DLBCLs), a class of DLBCLs that respond poorly to current therapies, chromosomal translocations and amplification lead to constitutive expression of the B cell lymphoma 6 (BCL6) oncogene. The role of BCL6 in maintaining these lymphomas has not been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27482887
DOI: 10.1172/jci85795

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphomaPMID 27482887Read ↗

Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomasSemantic proximity Read ↗

Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and BeyondSemantic proximity Read ↗

BCL6 as a therapeutic target for lymphoma.Semantic proximity Read ↗

Diffuse large B cell lymphoma: molecular targeted therapy.Semantic proximity Read ↗

Novel Small Molecule DZ-865B Effectively Degrades BCL6, Promotes Apoptosis and Reduces Proliferation of Diffuse Large B-Cell Lymphoma CellsSemantic proximity Read ↗

B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and BeyondSemantic proximity Read ↗

Leveraging the BAF chromatin remodeling complex for targeted transcriptional rewiring in cancerSemantic proximity Read ↗

FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.Semantic proximity Read ↗

Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic ImplicationsSemantic proximity Read ↗

Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomasSemantic proximity Read ↗

Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCLSemantic proximity Read ↗

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.